AASLD/EASL HBV Treatment Endpoints Workshop

Published on 29/08/2016

September 08-09, 2016

Alexandria, VA, USA

AASLD and EASL possess the expertise in chronic hepatitis B and D to bridge the current knowledge gaps that regulatory and pharmaceutical industry has identified as important issues hampering development of novel therapeutic agents for chronic hepatitis B and D.

This workshop will bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

http://www.aasld.org/events-professional-development/aasldeasl-hbv-treatment-endpoints-workshop?&utm_source=homepage&utm_medium=HBVEndpoints&utm_campaign=rotator

poster aasld-2016-eposter-radreau-et-al

Read next in 'Events'

• Alport Connect 2024, the annual Alport syndrome patient and family meeting in US
• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week